Medincell (STU:MEB) Debt-to-Revenue : 4.53 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Medincell Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Medincell's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €10.06 Mil. Medincell's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €53.18 Mil. Medincell's annualized Revenue for the quarter that ended in Sep. 2023 was €13.97 Mil. Medincell's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 was 4.53.

Medincell Debt-to-Revenue Historical Data

The historical data trend for Medincell's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell Debt-to-Revenue Chart

Medincell Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Revenue

Get a 7-Day Free Trial

18.74

11.87

5.30

11.61

5.80

Medincell Semi-Annual Data
	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Revenue	Get a 7-Day Free Trial										14.13	9.52	4.02	7.37	4.53

Competitive Comparison of Medincell's Debt-to-Revenue

For the Biotechnology subindustry, Medincell's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medincell's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medincell's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Medincell's Debt-to-Revenue falls into.

Medincell Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Medincell's Debt-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(43.456	+	14.252)	/	9.944
	=	5.80

Medincell's annualized Debt-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(10.055	+	53.175)	/	13.97
	=	4.53

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Sep. 2023) Revenue data.

Medincell Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Medincell's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (STU:MEB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (STU:MEB) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

MEDCL:France MEB:Germany

Address

3 rue des Freres Lumiere, Jacou, FRA, 34830

Website

https://www.medincell.com

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (STU:MEB) Headlines

No Headlines